Connect
Does anyone have a solution to help manage Reclast side effects?
Does anyone have a solution to combat Reclast side effects. I had the infusion a year and a half ago and the side effects started shortly after I had the infusion. I still have weak legs, swelling in feet, pain in bones, dizziness (serious dizziness), cold sweats, tired all the time and nervous twitching in bones. Any suggestions?
Like
Helpful
HugInterested in more discussions like this? Go to the Osteoporosis & Bone Health Support Group.
Connect
Eventually I was able to view and print it out!
I do hope it is okay to share here! Thank You for sharing this with me!
Immune-mediated syndromes following intravenous bisphosphonate therapy
Reclast infusion
https://link.springer.com/article/10.1007/s10787-017-0365-9
Abstract
Objectives
Intravenous (IV) infusion of aminobisphosphonates (ABP) induces cytokine release by peripheral blood Vγ9δ2 T cells, resulting in an immediate short-term inflammatory response in up to 50% of patients. We evaluated possible long-term pro-inflammatory effects of IV ABP.
Methods
Retrospective case-series study from one rheumatology specialist’s clinic. 2261 electronic charts were reviewed for administration of ‘zoledronate’ or different brand names of zoledronic acid, and relevant clinical data was retrieved for patients who had received the infusion.
Results
Thirteen patients had recieved zoledronate. In six, new-onset or exacerbation of a previous inflammatory/autoimmune disorder was diagnosed within 3 months following infusion. Of these, one patient developed new-onset rheumatoid arthritis (RA), two polymyalgia rheumatica (PMR), two suffered a flare of Crohn’s disease-related and aromatase inhibitor-induced arthralgias, and one patient acquired autoimmune hemophilia. Pre-existing malignancy and immediate inflammatory response following zoledronate were more frequent in patients experiencing new or worsening immunologic manifestations (3/6 vs. 0/7, and 5/6 vs. 2/7, respectively).
Conclusions
Intravenous ABP may trigger induction of persistent autoimmune syndromes, especially when accompanied by an immediate adverse reaction or pre-existing malignancy.
It is all from the infusion
My bones are inflamed because of the remodeling caused by Reclast
My endocrinologist says she is very sorry, is one case in a million!!
Well I am that one case and my life has been turned upside down
My pain is in the bones of my left femur and my ribs
I can’t sleep or function
After all kind of testing they determined it is not my heart
My misery is the same
I wish it was a heart attack and be done with it, but no I have to live with these side effects
I sympathize with you
-
Like -
Helpful -
Hug
2 ReactionsPlease, do not give up! I’ve been going to physical therapy and it has been helping some! You now know that it is not from an injury! And, because of this you can make it get better over time. I try to stay as active as possible and do try to keep up with my exercise! My worst is now my left foot and sleep! I am better able to handle the pain in my shoulders throughout the day but at night, the smallest move and my shoulder pain wakes me right up. I am able to go back to sleep despite my sleep being disrupted by the pain. It takes some ambition on my part and I am not going to allow this medication to ruin my total life! Stay positive and it will get some better, hopefully completely better with time. In the meantime, No more bone density medication for me!
I also was provided this by a person on here!
Immune-mediated syndromes following intravenous bisphosphonate therapy
Reclast infusion
https://link.springer.com/article/10.1007/s10787-017-0365-9
Abstract
Objectives
Intravenous (IV) infusion of aminobisphosphonates (ABP) induces cytokine release by peripheral blood Vγ9δ2 T cells, resulting in an immediate short-term inflammatory response in up to 50% of patients. We evaluated possible long-term pro-inflammatory effects of IV ABP.
Methods
Retrospective case-series study from one rheumatology specialist’s clinic. 2261 electronic charts were reviewed for administration of ‘zoledronate’ or different brand names of zoledronic acid, and relevant clinical data was retrieved for patients who had received the infusion.
Results
Thirteen patients had recieved zoledronate. In six, new-onset or exacerbation of a previous inflammatory/autoimmune disorder was diagnosed within 3 months following infusion. Of these, one patient developed new-onset rheumatoid arthritis (RA), two polymyalgia rheumatica (PMR), two suffered a flare of Crohn’s disease-related and aromatase inhibitor-induced arthralgias, and one patient acquired autoimmune hemophilia. Pre-existing malignancy and immediate inflammatory response following zoledronate were more frequent in patients experiencing new or worsening immunologic manifestations (3/6 vs. 0/7, and 5/6 vs. 2/7, respectively).
Conclusions
Intravenous ABP may trigger induction of persistent autoimmune syndromes, especially when accompanied by an immediate adverse reaction or pre-existing malignancy.